Legend Biotech Concludes Successful 2025 Annual General Meeting

Legend Biotech ( (LEGN) ) just unveiled an update.

On June 12, 2025, Legend Biotech Corporation held its Annual General Meeting of Shareholders, where key resolutions were passed. Shareholders received the audited financial statements for 2024, ratified the appointment of Ernst & Young LLP as the independent auditor for 2025, re-elected three Class II directors, and authorized directors and officers to implement these resolutions. Approximately 92.8% of the ordinary shares were represented at the meeting, indicating strong shareholder engagement.

The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.

Spark’s Take on LEGN Stock

According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.

Legend Biotech’s overall score is driven by strong revenue growth and positive earnings call sentiment, but weighed down by continued unprofitability and cash flow issues. Technical indicators suggest caution, and the negative P/E ratio reflects current valuation concerns. Despite challenges, strategic initiatives and a solid cash position provide a positive outlook for future profitability.

To see Spark’s full report on LEGN stock, click here.

More about Legend Biotech

Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of novel therapies for oncology and other serious diseases.

Average Trading Volume: 1,659,203

Technical Sentiment Signal: Hold

Current Market Cap: $6.93B

For an in-depth examination of LEGN stock, go to TipRanks’ Overview page.